EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, Candice Lesage, Jean-Marie Michot, Ariane Lappara, Stephane Ederhy iD, Eric Assenat, Maxime Faure, Nahema Issa, Olivier Lambotte, Mathieu Puyade iD und 13 weitere

Journal for ImmunoTherapy of Cancer · 2023-05 · 11 (5) · e004792

DOI: 10.1136/jitc-2022-004792 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.05.2023. Verfasst von Cyrille Coustal und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, CHRU de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Myocarditis, Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecting any organ. Among these irAEs, myocarditis is rare but life-threatening.

Methods

We conducted a multicenter cross-sectional retrospective study with the aim of better characterizing ICI-related myocarditis. Myocarditis diagnosis was based on the recent consensus statement of the International Cardio-Oncology Society.

Results

Twenty-nine patients were identified, from six different referral centers. Most patients (55%) were treated using anti-programmed-death 1, rather than ICI combination (35%) or anti-programmed-death-ligand 1 (10%). Transthoracic echocardiography was abnormal in 52% of them, and cardiac magnetic resonance showed abnormal features in 14/24 patients (58%). Eleven patients (38%) were classified as severe. Compared with other patients, they had more frequently pre-existing systemic autoimmune disease (45% vs 6%, p=0.018), higher troponin level on admission (42-fold the upper limit vs 3.55-fold, p=0.001), and exhibited anti-acetylcholine receptor autoantibodies (p=0.001). Seven patients (24%) had myocarditis-related death, and eight more patients died from cancer progression during follow-up. Twenty-eight patients received glucocorticoids, 10 underwent plasma exchanges, 8 received intravenous immunoglobulins, and 5 other immunosuppressants. ICI rechallenge was performed in six patients, with only one myocarditis relapse.

Discussion

The management of ICI-related myocarditis may be challenging and requires a multidisciplinary approach. Prognostic features are herein described and may help to allow ICI rechallenge for some patients with smoldering presentation, after an accurate evaluation of benefit–risk balance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisAntineoplastic Agents, ImmunologicalNeoplasmsHumansImmune Checkpoint InhibitorsRetrospective StudiesCross-Sectional StudiesPrognosis

Stichwörter der Autor:innen

ImmunotherapyLung NeoplasmsMelanomaProgrammed Cell Death 1 Receptor

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, CHRU de Montpellier, Montpellier, France.
  • Department of Radiology, CHRU de Montpellier, Montpellier, France.
  • Department of thoracic oncology, Regional Cancer Centre Val d'Aurelle - Paul Lamarque, Montpellier, France.
  • Department of Dermatology, CHRU de Montpellier, Montpellier, France.
  • Gustave Roussy Institute, Villejuif, France.
  • Gustave Roussy, Villejuif, France.

ORCID-Profile: Stephane Ederhy, Mathieu Puyade, Jean-Luc Faillie, Alexandre Thibault Jacques Maria

Zitieren

APA

Coustal, C., Vanoverschelde, J., Quantin, X., Lesage, C., Michot, J. M., Lappara, A., Ederhy, S., Assenat, E., Faure, M., Issa, N., Lambotte, O., Puyade, M., Dereure, O., Tosi, D., Rullier, P., Serre, I., Larcher, R., Klouche, K., Chanques, G., …, & Maria, A. T. J. (2023). Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series. Journal for ImmunoTherapy of Cancer, 11(5), e004792. https://doi.org/10.1136/jitc-2022-004792

Vancouver

Coustal C, Vanoverschelde J, Quantin X, Lesage C, Michot JM, Lappara A, et al. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series. Journal for ImmunoTherapy of Cancer. 2023;11(5):e004792. doi:10.1136/jitc-2022-004792

BibTeX
@article{Coustal2023,
  author = {Coustal, Cyrille and Vanoverschelde, Juliette and Quantin, Xavier and Lesage, Candice and Michot, Jean-Marie and Lappara, Ariane and Ederhy, Stephane and Assenat, Eric and Faure, Maxime and Issa, Nahema and Lambotte, Olivier and Puyade, Mathieu and Dereure, Olivier and Tosi, Diego and Rullier, Patricia and Serre, Isabelle and Larcher, Romaric and Klouche, Kada and Chanques, Gérald and Vernhet-Kovacsik, Hélène and Faillie, Jean-Luc and Agullo, Audrey and Roubille, François and Guilpain, Philippe and Maria, Alexandre Thibault Jacques},
  title = {Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {5},
  pages = {e004792},
  doi = {10.1136/jitc-2022-004792}
}
Kostenlos starten →